Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography.
The chemokine receptor CXCR4 and its cognate ligand CXCL12 are pivotal for establishing metastases from many tumor types. Thus, CXCR4 may offer a cell surface target for molecular imaging of metastases, assisting diagnosis, staging, and therapeutic monitoring. Furthermore, noninvasive detection of CXCR4 status of a primary tumor may provide an index of the metastatic potential of the lesion. Here, we report the development and evaluation of [(64)Cu]AMD3100, a positron-emitting analogue of the stem cell mobilizing agent plerixafor to image CXCR4 in human tumor xenografts preselected for graded expression of this receptor. This imaging method was evaluated in lung metastases derived from human MDA-MB-231 breast cancer cells. Ex vivo biodistribution studies, performed to validate the in vivo imaging data, confirmed the ability of [(64)Cu]AMD3100 to image CXCR4 expression. Our findings show the feasibility of imaging CXCR4 by positron emission tomography using a clinically approved agent as a molecular scaffold.
Nimmagadda
Sridhar
S
Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, Maryland 21231, USA. snimmag1@jhmi.edu
Pullambhatla
Mrudula
M
Stone
Kristie
K
Green
Gilbert
G
Bhujwalla
Zaver M
ZM
Pomper
Martin G
MG
D000818:Animals; D001596:Benzylamines; D015153:Blotting, Western; D003301:Copper Radioisotopes; D000080027:Cyclams; D005260:Female; D005434:Flow Cytometry; D006571:Heterocyclic Compounds; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D049268:Positron-Emission Tomography; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed
D001596:Benzylamines; D003301:Copper Radioisotopes; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019718:Receptors, CXCR4; C088327:plerixafor
Bioorg Med Chem. 2009 Feb 15;17(4):1486-93
19188071
Cancer Lett. 2006 Jul 8;238(1):30-41
16046252
Nat Med. 1998 Jan;4(1):72-7
9427609
J Surg Res. 2010 Apr;159(2):689-95
19500800
J Surg Res. 2009 Aug;155(2):231-6
19482312
Cancer Res. 2004 Jun 15;64(12):4302-8
15205345
Ann Surg Oncol. 2008 Jan;15(1):281-5
17763975
J Biol Chem. 2001 Apr 27;276(17):14153-60
11154697
Curr Med Chem. 2007;14(21):2257-77
17896975
J Med Chem. 2004 Mar 11;47(6):1465-74
14998334
J Am Chem Soc. 2009 Mar 18;131(10):3416-7
19231846
Clin Cancer Res. 2000 Jan;6(1):102-11
10656438
J Biol Chem. 2003 Jun 13;278(24):21631-8
12690099
Nat Rev Drug Discov. 2003 Jul;2(7):581-7
12815382
J Nucl Med. 2009 Jul;50(7):1124-30
19525448
Clin Cancer Res. 2005 Aug 15;11(16):5686-93
16115904
J Nucl Med. 1997 Apr;38(4):536-44
9098198
Cancer Res. 2004 Dec 1;64(23):8604-12
15574767
Nature. 2005 Jul 28;436(7050):518-24
16049480
Clin Exp Metastasis. 2005;22(1):39-46
16132577
Nucl Med Biol. 2006 May;33(4):489-94
16720240
Ann Oncol. 2007 Jan;18(1):70-76
17032700
Nucl Med Biol. 1998 Aug;25(6):523-30
9751418
J Immunol. 1999 Sep 1;163(5):2368-72
10452968
Breast Cancer Res. 2003;5(5):R144-50
12927045
Breast Cancer Res Treat. 2006 Jun;97(3):275-83
16344916
Immunity. 1999 Apr;10(4):463-71
10229189
Blood. 2006 Mar 1;107(5):1761-7
16269611
Curr Pharm Des. 2007;13(1):3-16
17266585
Mod Pathol. 2006 May;19(5):738-45
16528367
Bioconjug Chem. 1991 Nov-Dec;2(6):415-21
1805938
Am J Pathol. 2008 Aug;173(2):545-60
18599607
Ann Oncol. 2009 Jun;20(6):1013-9
19237480
J Surg Res. 2007 Jul;141(1):53-9
17574038
J Virol. 1997 Oct;71(10):7478-87
9311827
J Cell Biochem. 2003 Jun 1;89(3):462-73
12761880
Antimicrob Agents Chemother. 2000 Jun;44(6):1667-73
10817726
FEBS Lett. 2003 Aug 28;550(1-3):79-83
12935890
J Surg Oncol. 1998 Oct;69(2):99-104
9808513
Biochemistry. 2003 Jan 28;42(3):710-7
12534283
Clin Cancer Res. 2006 Nov 15;12(22):6765-71
17121897
Breast. 2005 Oct;14(5):360-7
16216737
Cancer Res. 2005 Feb 1;65(3):967-71
15705897
FASEB J. 2004 Aug;18(11):1240-2
15180966
Nature. 2001 Mar 1;410(6824):50-6
11242036
J Immunol. 2000 Sep 15;165(6):3423-9
10975862
Clin Cancer Res. 2008 Dec 15;14(24):7975-80
19088012
Cancer Res. 2005 Jul 15;65(14):6178-88
16024619
Breast Cancer Res Treat. 2009 Jan;113(2):293-9
18270814
Bioconjug Chem. 1996 Jul-Aug;7(4):511-22
8853465